Technical Analysis for BWAY - Brainsway Ltd.

Grade Last Price % Change Price Change
C 5.53 -2.98% -0.17
BWAY closed down 6.4 percent on Wednesday, May 8, 2024, on 1.65 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
50 DMA Support Bullish -2.98%
Upper Bollinger Band Walk Strength -2.98%
Earnings Movers Other -2.98%
Wide Bands Range Expansion -2.98%
Overbought Stochastic Strength -2.98%
Gapped Down Weakness -2.98%
Stochastic Sell Signal Bearish -9.20%
Pocket Pivot Bullish Swing Setup -9.20%
Upper Bollinger Band Walk Strength -9.20%
Above Upper BB Strength -9.20%

   Recent Intraday Alerts

Alert Time
Fell Below 50 DMA 17 minutes ago
Fell Below 10 DMA 17 minutes ago
10 DMA Support about 1 hour ago
60 Minute Opening Range Breakdown about 1 hour ago
Down 5% about 1 hour ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience FDA Mental Health Opioids Stroke Multiple Sclerosis Psychiatry Major Depressive Disorder Neuromodulation Neurophysiology Depressive Disorder Smoking Neurotechnology Neuropsychology Post Traumatic Stress Disorder Smoking Cessation Treatment Of Major Depressive Disorder Obsessive Compulsive Disorder Addiction Neuromodulation Products Treatment Of Depression Non Invasive Neuromodulation Products

Is BWAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.615
52 Week Low 1.38
Average Volume 79,772
200-Day Moving Average 4.96
50-Day Moving Average 5.58
20-Day Moving Average 5.24
10-Day Moving Average 5.46
Average True Range 0.33
RSI (14) 55.75
ADX 16.18
+DI 29.57
-DI 22.04
Chandelier Exit (Long, 3 ATRs) 5.20
Chandelier Exit (Short, 3 ATRs) 5.59
Upper Bollinger Bands 6.04
Lower Bollinger Band 4.44
Percent B (%b) 0.79
BandWidth 30.42
MACD Line 0.09
MACD Signal Line -0.04
MACD Histogram 0.1304
Fundamentals Value
Market Cap 94.74 Million
Num Shares 16.6 Million
EPS -0.48
Price-to-Earnings (P/E) Ratio -11.88
Price-to-Sales 3.45
Price-to-Book 2.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.44
Resistance 3 (R3) 6.45 6.23 6.31
Resistance 2 (R2) 6.23 6.04 6.22 6.27
Resistance 1 (R1) 5.96 5.92 5.85 5.95 6.23
Pivot Point 5.74 5.74 5.68 5.73 5.74
Support 1 (S1) 5.47 5.55 5.36 5.46 5.17
Support 2 (S2) 5.25 5.43 5.24 5.13
Support 3 (S3) 4.98 5.25 5.09
Support 4 (S4) 4.97